Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... April 13, 2023 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 Load more HOT NEWS Embryos in the Womb Can Get Gene Mutations That Lead to... Physicians Debate Recent FDA Approval of an Immune Checkpoint Inhibitor in... Picking out the sound of tumours Making a startup out of a scientist
